Last reviewed · How we verify
SGN-CD33A
At a glance
| Generic name | SGN-CD33A |
|---|---|
| Also known as | vadastuximab talirine |
| Sponsor | Seagen Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDS (PHASE1, PHASE2)
- Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia (PHASE3)
- A Safety Study of SGN-CD33A in Combination With Standard-of-care in Patients With AML (PHASE1)
- A Safety Study of SGN-CD33A in AML Patients (PHASE1)
- Radiostereometric Analysis of Fracture Healing in Distal Femur Fractures
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- SGN-CD33A CI brief — competitive landscape report
- SGN-CD33A updates RSS · CI watch RSS
- Seagen Inc. portfolio CI